國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Rheumatic diseases and syndromes ind...

Calabrese, Leonard H.

Rheumatic diseases and syndromes induced by cancer immunotherapya handbook for diagnosis and management /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Rheumatic diseases and syndromes induced by cancer immunotherapyedited by Maria E. Suarez-Almazor, Leonard H. Calabrese.
其他題名:	a handbook for diagnosis and management /
其他作者:	Suarez-Almazor, Maria E.
出版者:	Cham :Springer International Publishing :2021.
面頁冊數:	xiv, 363 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Rheumatism.
電子資源:	https://doi.org/10.1007/978-3-030-56824-5
ISBN:	9783030568245$q(electronic bk.)

Rheumatic diseases and syndromes induced by cancer immunotherapya handbook for diagnosis and management /
Rheumatic diseases and syndromes induced by cancer immunotherapya handbook for diagnosis and management /[electronic resource] :edited by Maria E. Suarez-Almazor, Leonard H. Calabrese. - Cham :Springer International Publishing :2021. - xiv, 363 p. :ill. (some col.), digital ;24 cm.

PART 1 - INTRODUCTION -- 1. Cancer Immunology and the evolution of immunotherapy -- 2. Cancer immunotherapy: overview -- 3. Pathogenesis of immune-related adverse events -- PART 2 - IMMUNE-RELATED ADVERSE EVENTS WITH IMMUNE-CHECKPOINT INHIBITORS -- 4. Arthritis -- 5. Polymyalgia rheumatica -- 6. Myositis -- 7. Sicca syndromes -- 8. Sarcoidosis -- 9. Miscellaneous rheumatic syndromes -- 10. Non-rheumatic immune-related adverse events -- 11. Immune-related adverse events with other cancer immunotherapies -- PART 3 - CANCER IMMUNOTHERAPY IN PATIENTS WITH PRE-EXISTING RHEUMATIC DISEASES -- 12. Inflammatory arthritis -- 13. Other rheumatic autoimmune diseases -- 14. Choosing the right therapy -- 15. Risk-benefit considerations -- 16. Patient education and shared-decision making.

With the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumatic irAE have been reported with ICI therapy including arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like manifestations, and several other less common systemic autoimmune features commonly associated with connective tissue disease. This handbook provides clinicians with a comprehensive overview of the management of rheumatic irAE that develop from cancer immunotherapy. It focuses on the irAE seen with ICI, the most frequently used agents in treating cancer. It provides an overview of cancer immunology, immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-related adverse events arising from these therapies. Chapters also cover cancer immunotherapy in patients with preexisting rheumatic diseases such as inflammatory arthritis and other connective tissue disorders. The book helps clinicians to distinguish the current types of cancer immunotherapy and general toxicity patterns, recognize and diagnose rheumatic clinical syndromes, understand the pathogenesis of irAE, and consider risk-benefit ratios when managing patients with rheumatic irAE. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses alike in rheumatology, clinical immunology, oncology, and internal medicine.

ISBN: 9783030568245$q(electronic bk.)

Standard No.: 10.1007/978-3-030-56824-5doiSubjects--Topical Terms:

201924
Rheumatism.

LC Class. No.: RC927 / .R44 2021

Dewey Class. No.: 616.723

Rheumatic diseases and syndromes induced by cancer immunotherapya handbook for diagnosis and management /
LDR:03792nmm a2200325 a 4500 001 600694
003 DE-He213
005 20210216113734.0
006 m d
007 cr nn 008maaau
008 211104s2021 sz s 0 eng d
020 $a 9783030568245$q(electronic bk.)
020 $a 9783030568238$q(paper)
024 7 $a 10.1007/978-3-030-56824-5 $2 doi
035 $a 978-3-030-56824-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RC927 $b .R44 2021
072 7 $a MJM $2 bicssc
072 7 $a MED083000 $2 bisacsh
072 7 $a MJM $2 thema
082 0 4 $a 616.723 $2 23
090 $a RC927 $b .R472 2021
245 0 0 $a Rheumatic diseases and syndromes induced by cancer immunotherapy $h [electronic resource] : $b a handbook for diagnosis and management / $c edited by Maria E. Suarez-Almazor, Leonard H. Calabrese.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a xiv, 363 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a PART 1 - INTRODUCTION -- 1. Cancer Immunology and the evolution of immunotherapy -- 2. Cancer immunotherapy: overview -- 3. Pathogenesis of immune-related adverse events -- PART 2 - IMMUNE-RELATED ADVERSE EVENTS WITH IMMUNE-CHECKPOINT INHIBITORS -- 4. Arthritis -- 5. Polymyalgia rheumatica -- 6. Myositis -- 7. Sicca syndromes -- 8. Sarcoidosis -- 9. Miscellaneous rheumatic syndromes -- 10. Non-rheumatic immune-related adverse events -- 11. Immune-related adverse events with other cancer immunotherapies -- PART 3 - CANCER IMMUNOTHERAPY IN PATIENTS WITH PRE-EXISTING RHEUMATIC DISEASES -- 12. Inflammatory arthritis -- 13. Other rheumatic autoimmune diseases -- 14. Choosing the right therapy -- 15. Risk-benefit considerations -- 16. Patient education and shared-decision making.
520 $a With the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumatic irAE have been reported with ICI therapy including arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like manifestations, and several other less common systemic autoimmune features commonly associated with connective tissue disease. This handbook provides clinicians with a comprehensive overview of the management of rheumatic irAE that develop from cancer immunotherapy. It focuses on the irAE seen with ICI, the most frequently used agents in treating cancer. It provides an overview of cancer immunology, immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-related adverse events arising from these therapies. Chapters also cover cancer immunotherapy in patients with preexisting rheumatic diseases such as inflammatory arthritis and other connective tissue disorders. The book helps clinicians to distinguish the current types of cancer immunotherapy and general toxicity patterns, recognize and diagnose rheumatic clinical syndromes, understand the pathogenesis of irAE, and consider risk-benefit ratios when managing patients with rheumatic irAE. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses alike in rheumatology, clinical immunology, oncology, and internal medicine.
650 0 $a Rheumatism. $3 201924
650 0 $a Immunologic diseases. $3 229419
650 0 $a Cancer $x Immunotherapy $x Complications $3 895341
650 1 4 $a Rheumatology. $3 276701
650 2 4 $a Oncology. $3 195181
650 2 4 $a Immunology. $3 189152
700 1 $a Suarez-Almazor, Maria E. $3 895339
700 1 $a Calabrese, Leonard H. $3 895340
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-56824-5
950 $a Medicine (SpringerNature-11650)